600572 康恩贝
已收盘 11-06 15:00:00
资讯
新帖
简况
康恩贝(600572)11月5日主力资金净买入79.08万元
证券之星 · 08:33
康恩贝(600572)11月5日主力资金净买入79.08万元
康恩贝(600572)披露2022年股票期权激励计划首次授予第三个行权期符合行权条件的公告,11月05日股价下跌0.46%
证券之星 · 11-05 22:40
康恩贝(600572)披露2022年股票期权激励计划首次授予第三个行权期符合行权条件的公告,11月05日股价下跌0.46%
康恩贝(600572)11月3日主力资金净买入308.56万元
证券之星 · 11-04 08:35
康恩贝(600572)11月3日主力资金净买入308.56万元
股市必读:康恩贝(600572)10月30日董秘有最新回复
证券之星 · 11-02
股市必读:康恩贝(600572)10月30日董秘有最新回复
康恩贝(600572)10月30日主力资金净卖出657.02万元
证券之星 · 10-31
康恩贝(600572)10月30日主力资金净卖出657.02万元
康恩贝(600572)2026年三季报简析:增收不增利
证券之星 · 10-30
康恩贝(600572)2026年三季报简析:增收不增利
康恩贝:截至10月20日,公司股东总户数为89,707户
证券之星 · 10-30
康恩贝:截至10月20日,公司股东总户数为89,707户
康恩贝(600572)11.02万股限售股将于10月30日解禁,占总股本0%
证券之星 · 10-30
康恩贝(600572)11.02万股限售股将于10月30日解禁,占总股本0%
康恩贝走出胡季强时代
东方财富网 · 10-29
康恩贝走出胡季强时代
股市必读:康恩贝三季报 - 第三季度单季净利润同比下降18.13%
证券之星 · 10-29
股市必读:康恩贝三季报 - 第三季度单季净利润同比下降18.13%
图解康恩贝三季报:第三季度单季净利润同比下降18.13%
证券之星 · 10-28
图解康恩贝三季报:第三季度单季净利润同比下降18.13%
股市必读:康恩贝新发布《浙商证券股份有限公司关于浙江康恩贝制药股份有限公司股权分置改革部分限售股上市流通申请的核查意见》
证券之星 · 10-27
股市必读:康恩贝新发布《浙商证券股份有限公司关于浙江康恩贝制药股份有限公司股权分置改革部分限售股上市流通申请的核查意见》
康恩贝(600572)披露股改限售股上市流通公告,10月26日股价上涨1.43%
证券之星 · 10-26
康恩贝(600572)披露股改限售股上市流通公告,10月26日股价上涨1.43%
股市必读:康恩贝新发布《关于2022年股票期权激励计划限制行权期间的提示性公告》
证券之星 · 10-19
股市必读:康恩贝新发布《关于2022年股票期权激励计划限制行权期间的提示性公告》
康恩贝(600572)披露2022年股票期权激励计划限制行权期间的提示性公告,10月16日股价上涨0.23%
证券之星 · 10-16
康恩贝(600572)披露2022年股票期权激励计划限制行权期间的提示性公告,10月16日股价上涨0.23%
10月14日康恩贝发布公告,股东减持1000万股
证券之星 · 10-14
10月14日康恩贝发布公告,股东减持1000万股
康恩贝(600572.SH):康恩贝集团拟减持不超1%股份
智通财经 · 10-14
康恩贝(600572.SH):康恩贝集团拟减持不超1%股份
康恩贝:进入“十五五”阶段,公司在外延并购方面将聚焦做长长板
证券之星 · 10-09
康恩贝:进入“十五五”阶段,公司在外延并购方面将聚焦做长长板
康恩贝:公司当前暂无发行超短期融资券、中期票据安排
证券之星 · 10-09
康恩贝:公司当前暂无发行超短期融资券、中期票据安排
康恩贝:截至9月30日,公司股东总户数为90,869户
证券之星 · 10-09
康恩贝:截至9月30日,公司股东总户数为90,869户
加载更多
公司概况
公司名称:
浙江康恩贝制药股份有限公司
所属行业:
医药制造业
上市日期:
2004-04-12
主营业务:
浙江康恩贝制药股份有限公司的主营业务是药品、中药材饮片及健康消费品的研发、制造与销售业务。公司的主要产品是“前列康”普乐安片及胶囊、“天保宁”银杏叶制剂、“康恩贝”肠炎宁、“金奥康”奥美拉唑产品、“金笛”复方鱼腥草合剂、“金艾康”汉防己甲素、“金康速力”乙酰半胱氨酸泡腾片、“至心砃”麝香通心滴丸、“康恩贝”“宝芝林”“养营堂”品牌系列保健食品和功能性食品。公司工业树种选育与产业关键技术项目获国家科学技术进步二等奖、数智中药大健康产业体系及应用项目获浙江省科学技术进步二等奖。
发行价格:
8.25
{"stockData":{"symbol":"600572","market":"SH","secType":"STK","nameCN":"康恩贝","latestPrice":4.26,"timestamp":1793948400000,"preClose":4.35,"halted":0,"volume":45414026,"delay":0,"changeRate":-0.0207,"floatShares":2534000000,"shares":2541000000,"eps":0.1798,"marketStatus":"已收盘","change":-0.09,"latestTime":"11-06 15:00:00","open":4.3,"high":4.3,"low":4.21,"amount":193000000,"amplitude":0.0207,"askPrice":4.26,"askSize":3002,"bidPrice":4.25,"bidSize":176,"shortable":0,"etf":0,"ttmEps":0.1798,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":4.35,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":4.79,"lowLimit":3.91,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2540530151,"isCdr":false,"pbRate":1.49,"roa":"--","peRate":23.692992,"roe":"7.89%","epsLYR":0.19,"committee":0.16041,"marketValue":10823000000,"turnoverRate":0.0179,"status":1,"floatMarketCap":10794000000},"requestUrl":"/m/hq/s/600572","defaultTab":"news","newsList":[{"id":"2681888454","title":"康恩贝(600572)11月5日主力资金净买入79.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681888454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681888454?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:33","pubTimestamp":1793925212,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月5日收盘,康恩贝报收于4.35元,下跌0.46%,换手率1.59%,成交量40.24万手,成交额1.75亿元。近5日资金流向一览见下表:康恩贝融资融券信息显示,融资方面,当日融资买入1454.54万元,融资偿还1382.17万元,融资净买入72.38万元。融券方面,融券卖出2.13万股,融券偿还1.4万股,融券余量38.87万股,融券余额169.08万元。康恩贝主营业务:药品、中药饮片及大健康产品的研发、制造及销售业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600008693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0060","600572","BK0097","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681074114","title":"康恩贝(600572)披露2022年股票期权激励计划首次授予第三个行权期符合行权条件的公告,11月05日股价下跌0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681074114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681074114?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:40","pubTimestamp":1793889625,"startTime":"0","endTime":"0","summary":"截至2026年11月5日收盘,康恩贝报收于4.35元,较前一交易日下跌0.46%,最新总市值为110.51亿元。近日,浙江康恩贝制药股份有限公司披露《关于2022年股票期权激励计划首次授予股票期权第三个行权期符合行权条件的公告》。公司于2026年11月5日召开董事会,审议通过相关议案。行权期为2026年11月30日至2027年11月26日间的交易日,采用自主行权方式。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500043291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600572","BK0188","BK0239","BK0097","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680965701","title":"康恩贝(600572)11月3日主力资金净买入308.56万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680965701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680965701?lang=zh_cn&edition=full","pubTime":"2026-11-04 08:35","pubTimestamp":1793752523,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月3日收盘,康恩贝报收于4.36元,上涨2.35%,换手率2.49%,成交量62.98万手,成交额2.73亿元。近5日资金流向一览见下表:康恩贝融资融券信息显示,融资方面,当日融资买入1268.47万元,融资偿还1987.67万元,融资净偿还719.2万元。康恩贝主营业务:药品、中药饮片及大健康产品的研发、制造及销售业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400010896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600572","BK0188","BK0097","BK0239","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680788056","title":"股市必读:康恩贝(600572)10月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680788056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680788056?lang=zh_cn&edition=full","pubTime":"2026-11-02 07:04","pubTimestamp":1793574256,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘,康恩贝报收于4.21元,上涨0.96%,换手率1.92%,成交量48.62万手,成交额2.05亿元。董秘最新回复投资者: 请问截止2026年10月20日,公司股东人数是多少户?截至10月20日,公司股东总户数为89,707户。当日关注点交易信息汇总:10月30日主力资金净流出657.02万元,占总成交额3.21%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0060","BK0028","BK0239","BK0012","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679226740","title":"康恩贝(600572)10月30日主力资金净卖出657.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679226740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679226740?lang=zh_cn&edition=full","pubTime":"2026-10-31 08:22","pubTimestamp":1793406137,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月30日收盘,康恩贝报收于4.21元,上涨0.96%,换手率1.92%,成交量48.62万手,成交额2.05亿元。近5日资金流向一览见下表:康恩贝融资融券信息显示,融资方面,当日融资买入839.18万元,融资偿还1416.97万元,融资净偿还577.79万元。康恩贝主营业务:药品、中药饮片及大健康产品的研发、制造及销售业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100018267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","600572","BK0060","BK0188","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679378246","title":"康恩贝(600572)2026年三季报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2679378246","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679378246?lang=zh_cn&edition=full","pubTime":"2026-10-30 23:57","pubTimestamp":1793375874,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期康恩贝发布2026年三季报。根据财报显示,康恩贝增收不增利。截至本报告期末,公司营业总收入53.3亿元,同比上升7.12%,归母净利润5.66亿元,同比下降3.02%。持有康恩贝最多的基金为工银中证1000指数增强A,目前规模为9.14亿元,最新净值1.1647,较上一交易日上涨0.0%,近一年下跌14.01%。本文数据来源于康恩贝2026年三季报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000059212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600572","BK0012","BK0097","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679986462","title":"康恩贝:截至10月20日,公司股东总户数为89,707户","url":"https://stock-news.laohu8.com/highlight/detail?id=2679986462","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679986462?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:27","pubTimestamp":1793348832,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝(600572)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司截止2026年10月20日的股东户数是多少?谢谢康恩贝回复:尊敬的投资者您好!截至10月20日,公司股东总户数为89,707户。感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000039723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0060","BK0012","600572","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679825553","title":"康恩贝(600572)11.02万股限售股将于10月30日解禁,占总股本0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679825553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679825553?lang=zh_cn&edition=full","pubTime":"2026-10-30 08:04","pubTimestamp":1793318666,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,康恩贝于10月30日将有11.02万股限售股份解禁,为公司股权分置限售股份,占公司总股本0.0%。本次解禁后,公司还有663.17万股限售股份,占总股本0.26%。康恩贝主营业务:药品、中药饮片及大健康产品的研发、制造及销售业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000014637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0060","BK0097","BK0028","600572","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679444960","title":"康恩贝走出胡季强时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2679444960","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679444960?lang=zh_cn&edition=full","pubTime":"2026-10-29 09:22","pubTimestamp":1793236925,"startTime":"0","endTime":"0","summary":"10月28日,康恩贝公告称,公司于前三季度实现营收53.3亿元,同比增长7%;实现归母净利润5.66亿元,同比下降3%。第三季度内,企业实现营收16.29亿元,与同期几乎持平;实现归母净利润1.89亿元,同比下降18.13%。但在扣非净利润一项,康恩贝于前三季度实现扣非净利润6亿元,同比增加40%;第三季度扣非净利润为1.8亿元,同比增加30%。这意味着,企业的盈利能力在改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11215,202610293913265463.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11215,202610293913265463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK0012","BK0097","BK0060","BK0239","BK0188","600572","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679041932","title":"股市必读:康恩贝三季报 - 第三季度单季净利润同比下降18.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679041932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679041932?lang=zh_cn&edition=full","pubTime":"2026-10-29 04:07","pubTimestamp":1793218061,"startTime":"0","endTime":"0","summary":"截至2026年10月28日收盘,康恩贝报收于4.16元,下跌0.24%,换手率1.72%,成交量43.59万手,成交额1.8亿元。股本股东变化:截至2026年9月30日,康恩贝股东户数为9.09万户,较9月18日减少531户,减幅0.58%,户均持股增至2.8万股。业绩披露要点:康恩贝2026年前三季度归母净利润5.66亿元,同比下降3.02%;扣非净利润6.05亿元,同比上升40.35%;第三季度扣非净利润1.8亿元,同比上升33.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900004225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678783107","title":"图解康恩贝三季报:第三季度单季净利润同比下降18.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678783107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678783107?lang=zh_cn&edition=full","pubTime":"2026-10-28 02:45","pubTimestamp":1793126733,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝2026年三季报显示,前三季度公司主营收入53.3亿元,同比上升7.12%;归母净利润5.66亿元,同比下降3.02%;扣非净利润6.05亿元,同比上升40.35%;其中2026年第三季度,公司单季度主营收入16.29亿元,同比上升0.71%;单季度归母净利润1.89亿元,同比下降18.13%;单季度扣非净利润1.8亿元,同比上升33.67%;负债率29.54%,投资收益5680.71万元,财务费用-205.18万元,毛利率56.17%。财报数据概要请见下图:本文数据来源于康恩贝2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800002994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678611483","title":"股市必读:康恩贝新发布《浙商证券股份有限公司关于浙江康恩贝制药股份有限公司股权分置改革部分限售股上市流通申请的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678611483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678611483?lang=zh_cn&edition=full","pubTime":"2026-10-27 04:56","pubTimestamp":1793048171,"startTime":"0","endTime":"0","summary":"公司公告汇总浙商证券股份有限公司关于浙江康恩贝制药股份有限公司股权分置改革部分限售股上市流通申请的核查意见中铁世纪传媒广告有限公司持有的110,160股限售股将于2026年10月30日上市流通;该股份源于北京京站国隆商贸中心历史持股,经康恩贝集团代垫对价后由中铁传媒承接;中铁传媒已偿还代垫款项并取得康恩贝集团同意;本次上市符合股权分置改革相关规定,相关承诺已履行完毕,不存在资金占用情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700006333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601878","BK0239","BK0060","600572","BK0012","BK0276","BK0028","BK0097","BK1191","01477","BK0188","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678237194","title":"康恩贝(600572)披露股改限售股上市流通公告,10月26日股价上涨1.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678237194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678237194?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:51","pubTimestamp":1793026276,"startTime":"0","endTime":"0","summary":"截至2026年10月26日收盘,康恩贝报收于4.27元,较前一交易日上涨1.43%,最新总市值为108.47亿元。近日,浙江康恩贝制药股份有限公司发布股改限售股上市流通公告。本次上市流通的股改为限售股份,数量为110,160股,上市流通日期为2026年10月30日。本次上市后,公司有限售条件的流通股减少110,160股,无限售条件的流通股相应增加。公告确认此次上市符合股权分置改革管理办法相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600038163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","600572","BK0239","BK0012","BK0028","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676648578","title":"股市必读:康恩贝新发布《关于2022年股票期权激励计划限制行权期间的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676648578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676648578?lang=zh_cn&edition=full","pubTime":"2026-10-19 01:23","pubTimestamp":1792344189,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘,康恩贝报收于4.27元,上涨0.23%,换手率1.98%,成交量50.11万手,成交额2.16亿元。当日关注点交易信息汇总:10月16日主力资金净流出1425.21万元,占总成交额6.6%; 公司公告汇总:康恩贝将于2026年10月23日至10月28日对2022年股票期权激励计划实施限制行权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0012","BK0188","BK0097","BK0060","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675518588","title":"康恩贝(600572)披露2022年股票期权激励计划限制行权期间的提示性公告,10月16日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675518588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675518588?lang=zh_cn&edition=full","pubTime":"2026-10-16 22:33","pubTimestamp":1792161198,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘,康恩贝报收于4.27元,较前一交易日上涨0.23%,最新总市值为108.47亿元。公告显示,根据相关规定及2026年第三季度报告披露计划,公司对2022年股票期权激励计划处于自主行权期间的股票期权实施限制行权。首次授予股票期权第二个行权期及预留授予股票期权第一个行权期的可行权期均为2025年11月28日至2026年11月27日。本次限制行权期为2026年10月23日至2026年10月28日,期间全部激励对象将限制行权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600040456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","600572","BK0239","BK0012","BK0028","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675345031","title":"10月14日康恩贝发布公告,股东减持1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675345031","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675345031?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:01","pubTimestamp":1791975677,"startTime":"0","endTime":"0","summary":"证券之星消息,10月14日康恩贝发布公告《康恩贝:关于公司股东集中竞价减持股份计划的公告》,其股东胡季强于2026年3月7日至2026年10月14日间合计减持1000.0万股,占公司目前总股本的0.3936%,变动期间该股股价上涨0.46%,截止10月14日收盘报4.38元。股东增减持详情见下表:根据康恩贝2026年中报公布的十大股东详情如下:本文数据来源于康恩贝公告,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400033607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0060","BK0097","BK0028","600572","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675310095","title":"康恩贝(600572.SH):康恩贝集团拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2675310095","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675310095?lang=zh_cn&edition=full","pubTime":"2026-10-14 17:56","pubTimestamp":1791971788,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康恩贝(600572.SH)发布公告,公司第二大股东康恩贝集团因发展自身业务的资金需求,拟自公告披露之日后15个交易日后的3个月内通过上海证券交易所以集中竞价交易的方式减持公司股份,拟减持股份数量不超过2540.3万股,拟减持比例不超过公司总股本的1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0012","BK0060","BK0097","BK0028","600572","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674837075","title":"康恩贝:进入“十五五”阶段,公司在外延并购方面将聚焦做长长板","url":"https://stock-news.laohu8.com/highlight/detail?id=2674837075","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674837075?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:21","pubTimestamp":1791537700,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝10月09日在投资者关系平台上答复投资者关心的问题。投资者提问:公司当初承诺在十四五期间,收购1-2家医药公司或上市公司,十四五期间都过完了,公司的承诺一直没兑现,现在都是十五五期间,公司还有计划进行并购或收购计划?公司在“十四五”期间积极筛选、跟进多个潜在医药并购标的,受医药行业市场环境等多重因素影响,相关并购事项未能落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900026666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0097","BK0239","600572","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674837019","title":"康恩贝:公司当前暂无发行超短期融资券、中期票据安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2674837019","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674837019?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:21","pubTimestamp":1791537699,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝(600572)10月09日在投资者关系平台上答复投资者关心的问题。投资者提问:关于公司发行中期票据和超短期融资券获准注册的公告,己披露很久了,公司计划什么时候开始融资?康恩贝回复:尊敬的投资者您好!公司申请注册发行额度各不超过10亿元人民币的超短期融资券、中期票据已于2025年9月完成中国银行间市场交易商协会注册。公司当前暂无发行超短期融资券、中期票据安排,后续将结合公司资金需求、融资规划及资本市场环境综合评估是否发行,若有相关进展将按监管要求及时履行信息披露义务。感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900026664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0060","BK0097","BK0239","600572","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883707","title":"康恩贝:截至9月30日,公司股东总户数为90,869户","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883707","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674883707?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:21","pubTimestamp":1791537687,"startTime":"0","endTime":"0","summary":"证券之星消息,康恩贝(600572)10月09日在投资者关系平台上答复投资者关心的问题。投资者提问:您好!请问截至9月30日公司股东人数是多少,谢谢康恩贝回复:尊敬的投资者您好!截至9月30日,公司股东总户数为90,869户。感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900026658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600572","BK0060","BK0012","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793963671403,"stockEarnings":[{"period":"1week","weight":0.0432},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0023},{"period":"6month","weight":0.023},{"period":"1year","weight":-0.0541},{"period":"ytd","weight":0.0116}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江康恩贝制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"89707人(较上一季度减少1.28%)","perCapita":"28246股","listingDate":"2004-04-12","address":"浙江省金华市兰溪市康恩贝大道1号","registeredCapital":"254053万元","survey":" 浙江康恩贝制药股份有限公司的主营业务是药品、中药材饮片及健康消费品的研发、制造与销售业务。公司的主要产品是“前列康”普乐安片及胶囊、“天保宁”银杏叶制剂、“康恩贝”肠炎宁、“金奥康”奥美拉唑产品、“金笛”复方鱼腥草合剂、“金艾康”汉防己甲素、“金康速力”乙酰半胱氨酸泡腾片、“至心砃”麝香通心滴丸、“康恩贝”“宝芝林”“养营堂”品牌系列保健食品和功能性食品。公司工业树种选育与产业关键技术项目获国家科学技术进步二等奖、数智中药大健康产业体系及应用项目获浙江省科学技术进步二等奖。","listedPrice":8.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康恩贝,600572,康恩贝股票,康恩贝股票老虎,康恩贝股票老虎国际,康恩贝行情,康恩贝股票行情,康恩贝股价,康恩贝股市,康恩贝股票价格,康恩贝股票交易,康恩贝股票购买,康恩贝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}